Overview

Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response

Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
The primary aim is to show whether a reduction in tumor related mRNAs and a panel of selected miRNAS can be used to personalize enzalutamide therapy. Furthermore the aim is to explore the relation between drug exposure and the decrease in the selected biomarkers and treatment response.
Details
Lead Sponsor:
Radboud University
Collaborator:
Astellas Pharma Europe B.V.